Terminated EARLY_PHASE1 INTERVENTIONAL NCT01317017

Cell Responses to IFN-gamma

Cellular Responses To Intradermal-Gamma (IFN-gamma) in Normal and Psoriatic Patients

Sponsor: Rockefeller University

Interventions Actimmune

Updated 6 times since 2017 Last updated: Mar 4, 2013 Started: Jul 31, 2010 Primary completion: May 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Unable to isolate sufficient cells from the skin biopsy to perform study experiments.

Other terminated trials from Rockefeller University

See all terminations from Rockefeller University

Other Plaque Psoriasis trials with similar outcome

Browse all Plaque Psoriasis trials

Listed as NCT01317017, this EARLY_PHASE1 trial focuses on Plaque Psoriasis and remains terminated or withdrawn. Sponsored by Rockefeller University, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated Phase 0

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rockefeller University

Data source: Rockefeller University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States